AbbVie to Acquire ImmunoGen for $10.1B

Share this


AbbVie to Acquire ImmunoGen for $10.1B


  • AbbVie announces the acquisition of ImmunoGen, including its Elahere antibody-drug conjugate (ADC) for platinum-resistant ovarian cancer in a $10.1B deal
  • As per the deal, AbbVie will purchase all outstanding shares of ImmunoGen at a rate of $31.26 per share. Additionally, the agreement provides AbbVie access to Elahere (mirvetuximab soravtansine-gynx), which received FDA accelerated approval last year
  • The deal, expected to close in mid-2024, & ImmunoGen's subsequent pipeline of ADCs will be made available to AbbVie

Ref: Finance Yahoo | Image: ImmunoGen

Related News:- ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions